Satellos Bioscience Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MSCL.V research report →
Companysatellos.com
Satellos Bioscience Inc. , a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process.
- CEO
- Francis Gleeson
- IPO
- 2008
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $63.16M
- P/E
- -1.76
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- -5.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.42%
- ROIC
- -20.67%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,322,437 · 0.00%
- EPS
- $-0.32 · 0.00%
- Op Income
- $-8,406,661
- FCF YoY
- -153.97%
Performance & Tape
- 52W High
- $0.85
- 52W Low
- $0.29
- 50D MA
- $0.50
- 200D MA
- $0.47
- Beta
- 1.21
- Avg Volume
- 75.81K
Get TickerSpark's AI analysis on MSCL.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MSCL.V Coverage
We haven't published any research on MSCL.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MSCL.V Report →